Data on the risk of tuberculosis (TB) reactivation with infliximab therapy in patients with inflammatory bowel disease (IBD) who are from countries where TB is particularly prevalent, such as India, remains limited. A recent study sought to evaluate the rate of tubercular reactivation with infliximab in a cohort of patients with IBD.
Data on the risk of tuberculosis (TB) reactivation with infliximab therapy in patients with inflammatory bowel disease (IBD) who are from countries where TB is particularly prevalent, such as India, remains limited. A recent study sought to evaluate the rate of TB reactivation with infliximab in a cohort of patients with IBD (ulcerative colitis [UC] and Crohn disease [CD]).
The study was designed as a retrospective analysis of a database comprising patients with IBD who had previously received at least 1 dose of infliximab. The researchers included 69 patients in the study, of whom 22 had been previously diagnosed with UC and 47 had been diagnosed with CD.
In total, 8 patients developed TB after infliximab therapy. The median duration after the first dose of infliximab to detection of TB was 19 weeks (range, 6-94 weeks). Of these 8 patients, 7 had CD and 1 had UC.
The study’s authors also found that the rate of TB reactivation was higher in patients with CD (14.9% versus 4.5%, P = .21), though the finding was not statistically significant. The rate of TB was also higher among patients with a past history of TB (25% versus 9.8%, respectively). The authors noted that the possibility of the patients who experienced TB recurrence having intestinal TB (and therefore a higher chance of reactivation) was negated by 2 patients already having received anti-tubercular therapy before diagnosis of CD.
In terms of response to infliximab therapy, the authors found that there was no worsening of intestinal symptoms after administration of infliximab, and only 1 patient who developed TB had a primary nonresponse to infliximab.
Though the researchers did note that the study was limited due to a smaller sample size, they were also able to identify clinically significant results which demonstrated that physicians should be cautious before administering anti—tumor necrosis factor (anti-TNF) therapy, as there is a high rate of TB with infliximab in Indian patients with IBD. The authors also stated that the current screening methods could be more effective, and further research should look to identify methods that more accurately predict TB after infliximab therapy.
Reference
Agarwal A, Kedia S, Jain S, et al. High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India. Intest Res. 2018; 16(4): 588-598. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223459/?rel=0" ?rel=0" . Published October 2018. Accessed December 20, 2018.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.